ICU sedation, delirium & recovery
Association between neuromuscular blocking agents and the development of intensive care unit-acquired weakness (ICU-AW): A systematic review with meta-analysis and trial sequential analysis
Pooled result · Development of ICU-AWResult — go to the resultOdds ratio 2.77 95% CI 1.98–3.88Authors' conclusion
This meta-analysis suggests that the use of NMBA might be implicated in the development of ICU-AW.
Study context
- Population
- Adults (RCTs and cohort studies reporting neuromuscular blocking agents (NMBA) use and ICU-AW)
- Participants
- 3,839 adults · 30 studies
- Comparison
- NMBA use vs no NMBA use
- Outcome
- Development of ICU-acquired weakness (ICU-AW)
Methodological detailstrial sequential analysis, GRADE certainty assessment, pre-specified subgroup analyses (sepsis, type of NMBA), 4 RCTs, 21 prospective and 5 retrospective cohorts, Mostly observational studies with high heterogeneity; RCTs at high risk of bias
- Trial sequential analysis
- GRADE certainty assessment
- Pre-specified subgroup analyses (sepsis, type of NMBA)
- 4 RCTs, 21 prospective and 5 retrospective cohorts
- Mostly observational studies with high heterogeneity; RCTs at high risk of bias
Pooled result
Development of ICU-AW
Odds ratio
2.77
95% CI 1.98–3.88
NMBA vs No NMBA
OR 2.77 (95% CI 1.98–3.88)
As reported in the abstract
Further pooled results
Trial sequential analysis: required information size
- Patients needed to provide evidence for beneficial or harmful effects
- 22,330
Original publication
Association between neuromuscular blocking agents and the development of intensive care unit-acquired weakness (ICU-AW): A systematic review with meta-analysis and trial sequential analysis. Anaesth Crit Care Pain Med. Published 16 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →